Objective: The aim of this study was to investigate whether milk fortified with folic acid enhances the folate status of humans and whether the presence of folate-binding proteins (FBP) in pasteurised milk affects the bioavailability of folic acid from fortified milk. In untreated and pasteurised milk, folate occurs bound to FBP, while FBP is (partly) denatured in ultra-high-temperature (UHT)-treated milk. The effect of FBP on folate bioavailability is still unclear. Design, subjects and setting: Healthy, free-living subjects (n ¼ 69) aged 18-49 y participated in a 4-week double-blind, placebo-controlled dietary intervention study. Intervention: In addition to a fully controlled diet, the subjects consumed each day 500 ml of pasteurised or UHT milk, either fortified or not with 200 mg folic acid. Results: Consumption of fortified milk increased folate concentrations in serum and in red blood cells (RBC) by 6.6-7.0 nmol/l (Po0.001) and 32-36 nmol/l (Po0.01), respectively. Similarly, plasma homocysteine concentrations were lowered 0.88-0.89 mmol/l (P ¼ 0.001) in subjects who consumed fortified milk. The bioavailability of folic acid from pasteurised milk relative to that of folic acid from UHT milk was 74-94% (NS), depending on the parameter used. Conclusions: Milk fortified to supply an additional 200 mg of folic acid/s substantially increased folate status, and decreased plasma total homocysteine concentrations in young, healthy subjects. Milk is therefore a suitable matrix for fortification to enhance the folate status in humans. No significant effect of endogenous FBP was found on the bioavailability of folic acid from milk.
Introduction
Low folate status can cause megaloblastic anaemia (Steinberg et al, 1983; Fishman et al, 2000) , increases the risk of neural tube defects (MRC Vitamin Study Research group, 1991; Daly et al, 1997) and is associated with increased risk of colon cancer (Glynn & Albanes, 1994) . Furthermore, inadequate folate intake can increase plasma homocysteine concentrations (Selhub et al, 1993) , which in turn is associated with increased risk for cardiovascular disease (Pancharuniti et al, 1994; Boushey et al, 1995; Verhoef et al, 1996; Rimm et al, 1998) . In many European countries where folic acid fortification is not yet permitted, folate intake is usually lower than recommended (De Bree et al, 1997) . Thus, although there is currently much debate over folate requirements for optimal health and function (O'Keefe et al, 1995; Daly et al, 1997; Lewis et al, 1999) , increasing folate intake of populations to recommended levels is desirable. It would thus appear that it is not feasible for the whole population to reach the recommended intake by the consumption of products naturally rich in folate such as fruits and vegetables (Brouwer et al, 1999a; Castenmiller et al, 2000; Riddell et al, 2000) . As a result, the consumption of fortified food products can be considered as an alternative or complementary approach to increase folate intakes (Riddell et al, 2000) .
Milk may be a suitable product for folic acid fortification in many Western countries. As a result of its high consumption, dairy products provide 10-15% of the daily folate intake in such countries, especially among the younger population (Forssén et al, 2000) . In addition, the presence of milk in the diet seems to enhance folate bioavailability compared to diets without milk (Wigertz et al 1997) , and Smith et al (1985) suggest from their study in infants that folate present in milk is more available than folates from other foods. The naturally occurring form of folate in untreated milk, 5-methyltetrahydrofolate (5-CH 3 -H 4 folate), is bound to folatebinding proteins (FBP) (Ghitis, 1967; Wagner, 1985; Wigertz et al, 1996) . FBP is (partly) denatured after ultra-hightemperature (UHT) treatment, and as a result folate could occur free in UHT milk. In pasteurised milk, FBP is only partly denatured by the heating and, as a result, folate remains bound to FBP (Wigertz et al, 1996) . Folate bound to FBP was found to be relatively unavailable to intestinal flora, and consequently FBP might enhance folate absorption from the gut (Ford, 1974) . FBP might also directly promote the transport of folate across the intestinal mucosa, although contradictory results have been reported (Colman et al, 1981; Tani et al, 1983; Salter & Blakeborough, 1988; Said et al, 1986) . Thus, the role of FBP in the bioavailability of folate is still a matter of debate.
The objectives of the present study were two-fold: firstly, to determine whether fortified milk can enhance the folate status in humans, and secondly, to determine the bioavailability of folic acid from pasteurised milk relative to that from UHT milk. For these purposes, serum folate, red blood cell (RBC) folate and plasma homocysteine levels were measured prior to and after a 4-week intervention period in which 69 healthy subjects consumed pasteurised or UHT milk either fortified or not with 200 mg folic acid per day.
Subjects and methods

Subjects
Subjects were recruited via advertisements in local and university newspapers and on posters in university buildings and student apartments. The study protocol was explained carefully to potential participants who were admitted to the study on signing an informed consent form. The study protocol was approved by the Medical Ethical Committee of Wageningen University. Subjects were eligible if they were between 18 and 50 y of age. Exclusion criteria were smoking, use of dietary supplements or yeast tablets during the 4 weeks prior to the study, use of malaria prophylactics or corticosteroids during the previous 3 months, abnormal fasting concentrations in urine of glucose or protein, abnormal haematology, blood haemoglobin concentrations o7.4 mmol/l in women or o8.5 mmol/l in men, or total plasma homocysteine concentrations 415 mmol/l.
Study design
The study comprised a 4-week run-in period followed by a 4-week double-blind intervention using four parallel dietary treatment groups. During the run-in period, subjects were allowed to choose their own diets but were instructed to avoid foods rich in folate. Before the dietary intervention period, subjects were stratified according to sex, self-reported energy intake and total plasma homocysteine concentration, and randomly allocated to one of four experimental groups. During the intervention period, all subjects received each day a basal diet plus 500 ml of one of the following semiskimmed milk products: pasteurised milk, pasteurised milk fortified with 200 mg folic acid, UHT milk or UHT milk fortified with 200 mg folic acid.
Folic acid (pteroylglutamic acid; Eprova, Schaffhausen, Switzerland) was added to unprocessed milk. After fortification, the milk was homogenised at 60-651C and divided into two portions. One-half of the milk was pasteurised (15 s, 761C) and one-half was processed following UHT treatment (15 s, 1401C). The unfortified milk was processed in the same way. Each milk product was assigned a colour code that was used to label the 250 ml sealed milk beakers, in order to blind the subjects and researchers to their content. The milk products were manufactured and supplied twice weekly by Campina Netherlands (Woerden, The Netherlands). The milk was stored at 41C and distributed daily to the subjects in insulated bags with a cooling element. The subjects were not allowed to heat the milk, and were instructed to drink the milk together with their bread meals (breakfast and evening meals), in order to diminish variations in uptake due to variations in food matrices.
The basal diet was changed daily on a weekly cycle and based on Dutch nutrition guidelines and recommendations (Voedingsraad, 1992) . Special care was taken to ensure that the folate and vitamin C content in the diets served each day were similar. On weekdays, the subjects received a hot meal at the Division of Human Nutrition of Wageningen University. Bread meals, milk, fruit and biscuits were packed for consumption at home, as was food and milk for the weekends together with instructions on how to prepare the food. To estimate habitual energy intake, the subjects completed a food frequency questionnaire (Feunekes et al, 1993) prior to the start of the study. We designed basal diets for 19 levels of energy intake, ranging from 7 to 25 MJ/day, and allocated the subjects to an intake level close to their energy requirements. All foods were weighed or counted for every subject. We recorded the body weight of the subjects twice each week and adjusted energy intake when necessary in order to maintain stable body weight. The food distributed provided 90% of the energy required to maintain body weight. For the remaining 10% of energy intake, subjects were allowed to choose from a list of foods low in fat and containing no folate. The daily selection of free choice food items was recorded in a diary, as were illnesses and deviations from the instructions.
Analysis of diets
Each day during the intervention period, one complete portion of the basal diet for an imaginary subject with a daily intake of approximately 11 MJ (ca. 1100 g) was collected for the analysis of macronutrients. The portions were stored at À201C. On completion of the intervention, the seven individual day portions of each week were thawed and mixed, resulting in one portion for every week. Samples of each of these week portions were refrozen at À201C. For the analysis of folate, another complete portion of the basal diet, but without milk, was collected daily and blended with 1 l of a freshly prepared 0.1 mol/l phosphate buffer (pH 6.1; Strålsjö et al, 2002) , with 2% (w/v) ascorbic acid, under a flow of nitrogen in order to reduce the risk of oxidation, and samples were stored at À801C. In addition, portions (ca. 500 g) of each of the four milk products were collected daily, mixed with ca. 5 g sodium ascorbate (1% (w/w)) (Sigma, St Louis, MO, USA) and stored at À801C until folate analysis.
The content of moisture and of ash in each weekly food portion was determined by heating in a vacuum oven at 851C and then in a muffle furnace at 5501C. Protein content was assessed by the Kjeldahl method using a conversion factor of 6.25; fat was measured by the acid hydrolysis method (AOAC Official Method 920.85, 1999); dietary fibre according to the AOAC Official Method for total dietary fibre (AOAC Official Method 992.16, 1996) ; and digestible carbohydrate was calculated by difference.
The total folate content of the milk and food samples was determined using a microbiological assay based upon the growth of the folate-requiring chloramphenicol-resistant Lactobacillus casei (NCBI 10463, ATCC, Manassas, VA, USA) (Williams, 1984) . The samples were extracted following a trienzyme method. Successively, 1-5 ml of the samples was incubated for 3 h with 1 ml protease (2 g/l; Sigma), 2 h with 1 ml amylase (20 g/l; Sigma) and at least 4 h with 4 ml of chicken pancreas preparation (Amano Pharmaceuticals, Nagoya, Japan). Afterwards, the samples were added to microtitre plates and mixed with incubation medium (folic acid casei medium, 0822-15-9, Difco), containing chloramphenicol, and inoculated with the Lactobacillus casei strain. After an incubation period of 18-22 h at 371C, absorbance was measured at 600 nm relative to the standard concentration curve of folic acid on each microtitre plate to measure the folate content of the samples.
The concentration of immunoreactive FBP in the milk products was quantified by a two-site ELISA (Høier-Madsen et al, 1986) as described earlier (Verwei et al, 2003) . The antibody against FBP from bovine milk (rabbit anti-bovine FBP 24740) and the FBP calibrant were obtained from the State Serum Institute (Copenhagen, Denmark) and the Central Hospital in Hillerød (Denmark), respectively. Interand intra-assay coefficients of variation (CVs) of folates and immunoreactive FBP did not exceed 15%.
Analysis of blood
Blood was taken from subjects after an overnight fast by venipuncture between 0715 and 1030 h on days 0, 1, 27 and 28 of the dietary intervention period. Blood samples collected for analysis of plasma homocysteine concentrations were immediately placed on ice and centrifuged within 30 min (41C, 1200 Â g, 10 min). Samples for serum folate and vitamin B 12 measurements were kept in the dark at room temperature for at least 30 min before centrifugation (41C, 1200 Â g, 10 min). Plasma and serum were stored at À801C. A third tube (EDTA K3E, Venoject, Terumo Europe NV, Leuven, Belgium) was filled with blood and placed in the dark. For analysis of whole-blood folate, one portion of this blood was diluted (1:9, (v/v)) with freshly prepared ascorbic acid solution (1%, (w/v)), mixed and immediately frozen in dry ice and stored at À801C. A second portion of the blood from this tube was kept at room temperature for measuring the haematocrit, which was required for calculating folate concentrations in RBCs. In addition, on the final day of the study, a portion of this blood was stored at À801C for determination of the 5,10-methylenetetrahydrofolate reductase (MTHFR) genotype. For the determination of serum folate, whole-blood folate and plasma homocysteine concentrations, all samples of each person sampled on days 0, 1, 27 and 28 were measured in the same run to eliminate interassay variation.
Whole-blood lysate samples (400 ml) were incubated for 60 min in a water bath at 371C for conversion to monoglutamyl forms. Subsequently, proteins were precipitated by the addition of 800 ml acetonitrile, and after mixing by vortex for 30 s and centrifuging (41C, 10 000 Â g, 10 min), the supernatant was evaporated to dryness under a flow of nitrogen at 501C and reconstituted in 250 ml of 0.1 M phosphate buffer (with 1%, (w/v) ascorbic acid, pH 7.0). As no folate compounds other than 5-CH 3 -H 4 folate were detected in the serum and blood samples (as measured in a subsample, data not shown), the analytical method was directed towards the determination of the 5-CH 3 -H 4 folate content. Concentrations of 5-CH 3 -H 4 folate in serum and blood were determined using reversed phase HPLC with fluorescence (excitation 290 nm, emission 360 nm) detection. An inertsil 5 OD-3 column (2 Â 10 cm, 3 mm i.d., Varian CP28308) was used in combination with a Chromsep guard column (10 Â 2 mm, Varian CP28141). A gradient elution with 0.033 M phosphate buffer (pH 2.1) and acetonitrile (HPLC-S grade) was used, and the start gradient was a mixture of phosphate buffer and acetonitrile (95:5 (v/v)) as described by Konings (1999) . Within-and between-run CVs for serum and whole-blood 5-CH 3 -H 4 folate were o5%. Folate concentration in RBCs was calculated from that in whole blood and serum, and from the haematocrit.
Plasma concentrations of total homocysteine (sum of all oxidised and reduced forms of homocysteine) were measured by HPLC and fluorimetric detection as described by Ubbink et al (1991) . Within-and between-run CVs were 2 and 7%, respectively. Vitamin B 12 concentrations in serum were determined with the Immulite 2000 Vitamin B12 Assay (DPC, Los Angeles, CA, USA). Within-and between-run CVs were 7 and 6%, respectively. Detection of the 677 C to T substitution in both alleles of the MTHFR gene was performed with a polymerase chain reaction, followed by restriction fragment length polymorphism analysis using the HinfI enzyme (Frosst et al, 1995) .
Statistics and calculations
All analyses were based on the 69 subjects who completed the intervention trial. For each subject, mean values for total plasma homocysteine, serum folate and RBC folate concentrations were calculated for day 0 and day 1 (baseline) and for day 27 and day 28 (week 4). All data are reported as mean7s.d. Serum folate and RBC folate concentrations were normally distributed. Total plasma homocysteine concentrations were positively skewed; thus, they were transformed to natural logarithms to normalise their distribution for statistical analyses. For each person, the response to treatment was calculated as the change in the measured parameter from the start to the end of the intervention period and those responses were used for statistical analyses. A 2 Â 2 factorial design was used to examine if the addition of folic acid to milk increased serum and erythrocyte folate concentrations and decreased plasma homocysteine concentrations and if there was any difference in these responses between UHT and pasteurised milk (two-way analysis of variance, ANOVA). If the ANOVA indicated an overall significant effect of supplementation or type of milk (Po0.05), the treatment means were compared with Student's unpaired t-tests. All statistical analyses were carried out using SPSS for Windows 11.0 (SPSS Inc., Chicago, IL, USA).
We calculated the bioavailability of folic acid added to pasteurised milk relative to that of folic acid added to UHT milk using the formula:
where 'Effect past ' corresponds to the difference in serum or RBC folate concentrations of the fortified pasteurised milk group compared to that in the unfortified pasteurised milk group, 'Effect UHT ' refers to the differences with respect to the UHT milk groups, while 'FA UHT ' and 'FA past ' refer to the folic acid content of the fortified UHT and pasteurised milk compared to the unfortified milks, respectively. Relative bioefficacy was calculated from the ratio of the differences in plasma homocysteine concentrations.
Results
Of the 72 eligible subjects who started the intervention, seven had been unable to participate fully in the run-in period. As they were divided among the four intervention groups, we performed our analyses on data of all subjects. Linear regression analysis showed that run-in period as a dummy variable did not contribute significantly to serum folate status at 4 weeks (data not shown), and consequently did not affect our conclusions. Three subjects withdrew during the intervention period: one because of illness unrelated to the intervention and two for personal reasons. The median age of the participants was 21 y and 80% were women (Table 1) . Subject characteristics did not differ statistically significant among the four treatment groups. Their serum vitamin B 12 concentrations were within the normal range (118-590 pmol/l), except for one woman in the fortified UHT milk group, who had a relatively low serum vitamin B 12 concentration of 100 pmol/l. The mean total intake of folate, macronutrients and energy during the intervention period are shown in Table 2 . Compliance to the diet was very high as nearly all subjects consumed the expected 56 beakers (250 ml each) of milk. Two subjects failed to consume one beaker and one subject failed to consume 2.5 beakers of milk. The folate content of the free choice items was negligible. The energy intake from the free choice items was on average 11% of total energy. The folate concentrations in the unfortified and fortified UHT milk, 40 and 402 mg/l respectively, were slightly lower than in the unfortified and fortified pasteurised milk, 46 and 466 mg/l, respectively (Table 3 ). The concentration of immunoreactive FBP in the pasteurised milk was 140-160 nmol/l, while no immunoreactive FBP was detected in the UHT milk (Table 3) . This results in molar ratios between immunoreactive FBP and folate of approximately 1:0.6 and 1:7.5 in the unfortified and fortified pasteurised milk, respectively. Baseline serum folate, RBC folate and total plasma homocysteine concentrations were not significantly different among the four intervention groups (Table 4) . Folic acid supplementation increased both serum and RBC folate and decreased plasma homocysteine concentrations. The twofactor ANOVA showed no interaction between addition of folate and type of milk. The addition of folate significantly affected all three study parameters (Po0.0001), whereas the type of milk did not significantly affect any of the study parameters. As we found that the content of folate was slightly different for the two supplemented milk groups, we carried out the same statistical analysis correcting for the amount of folate in the groups. Therefore, the responses were expressed per unit of folate and the statistical analyses were repeated, assuming that serum folate concentrations in the range studied increase linearly with folate dose (Van Oort et al, 2003) . These analyses resulted in the same conclusions The FBP content of both pasteurised milks are significantly different from both UHT milks, Po0.001; pasteurised milk þ folic acid is different from pasteurised milk, P ¼ 0.05. Plasma homocysteine (mmol/l) c Week 0 8.7 (7.9-9.6) 8.6 (7.5-9.8) 8.4 (7.5-9.4) 8.6 (8.1-9.2) Week 4 9.1 (8.2-10.0) 8.0 (7.0-9.1) 8.9 (8.1-9.9) 8.0 (7.5-8. Values are given as geometric mean (95% CI). d Based on the log-transformed data used for statistical analysis, the ratio of geometric means of the fortified milk groups relative to the corresponding unfortified milk group at week 4, adjusted for baseline values (95% CI within parentheses). Significant difference between the fortified milk groups and their corresponding unfortified milk groups (Po0.0001).
as described above. The bioavailability of folic acid added to pasteurised milk relative to folic acid added to UHT milk, according to serum folate concentrations was 81% (95% CI: 50-111%). Based on RBC folate concentrations, this relative bioavailability was 94% (95 CI: 28-160%). Relative bioefficacy based on plasma homocysteine concentrations was 74% (95% CI: 17-132%).
The MTHFR-genotype distribution of subjects over homozygote wild-type (CC), heterozygote type (CT) and homozygote mutant type (TT) was 48, 46 and 6%, respectively (Table 1) . There were no differences in response of CT or TT subjects, but the number of subjects was too low to expect differences to be found.
Discussion
The present study showed that an extra daily dose of 200 mg folic acid added to milk significantly increased concentrations of folate in serum and RBCs and decreased plasma homocysteine concentrations within 4 weeks in adults with a relatively low natural dietary folate intake. This indicates that milk is a suitable matrix to enhance the folate status in countries where milk is commonly consumed. Fortification of food products is not yet allowed in the Netherlands in contrast to some other countries such as the USA, where fortification of bread and grain is found to be an effective strategy for the enhancement of folate status. In our study, folic acid from fortified milk was found to elevate serum folate concentrations and reduce plasma total homocysteine concentrations to a similar extent as folic acid from fortified breakfast cereals (Schorah et al, 1998) .
Folic acid appeared to be equally bioavailable from pasteurised milk and from UHT milk based on the serum folate concentrations, RBC folate concentrations and plasma homocysteine concentrations. Owing to the study design, we were not able to calculate the absolute bioavailability of folic acid added to milk; however, we can expect a relatively high bioavailability as in our study folic acid from fortified milk was found to have comparable effects on serum folate concentrations and plasma homocysteine concentrations as folic acid from supplements (Brouwer et al, 1999a, b) .
UHT treatment of milk led to a decrease in folate and immunoreactive FBP concentrations, which is in agreement with earlier findings by Wigertz et al (1996) . No immunoreactive FBP could be detected in UHT milk, while pasteurised milk contained 140-160 nmol FBP/l. In the fortified pasteurised milk, the amount of folic acid was 7.5 times higher than the amount of FBP (Table 3 ). According to Salter et al (1981) , 1 molecule FBP binds 1 molecule of folate at pH 7.2. Thus, only a small amount of the added folic acid is expected to be bound to FBP in the fortified pasteurised milk. This might explain why no difference in bioavailability of folic acid was found from pasteurised milk compared with UHT milk. These results are in line with an earlier study with subjects with an ileostomy, who consumed milk products either with or without endogenous FBP, together with a standardised diet daily for 3 weeks (Wigertz et al, 1997) . No difference in total 5-CH 3 -H 4 folate excretion in the ileostomal effluent was found between the two groups, indicating similar absorption and thus no effect of endogenous FBP on folate bioavailability.
The folic acid-fortified milk products tested in the present study were also studied in an in vitro dynamic gastrointestinal model (Verwei et al, 2003) and a small but nonsignificant difference was found between the proportion of folic acid from pasteurised milk that was bioaccessible (58%) compared with that from UHT milk (61%). The bioaccessible folic acid corresponds to the folate fraction, which is released from the food matrix and available for absorption in the small intestine. Folate transport across the intestinal cells is not studied using the in vitro gastrointestinal model, but can be studied in vitro using intestinal segments or cultured mucosal cells (eg Caco-2 cells). In our previous studies with monolayers of Caco-2 cells, we found that the intestinal transport and cellular accumulation of folic acid and 5-CH 3 -H 4 folate was decreased in the presence of FBP (Verwei et al, 2004) . Thus, the slightly lower bioaccessible proportion, as found in the studies with the gastrointestinal model, may indicate that the higher amount of FBP in the small intestine inhibits folate absorption. The effect of additional FBP on the bioaccessibility of folic acid from UHT or pasteurised milk was also studied in vitro (Verwei et al, 2003) . After addition of FBP, in a 1:1 molar ratio with folic acid, the proportion of folic acid that was bioaccessible was significantly (Po0.05) decreased compared with the folic acid-fortified pasteurised milk without additional FBP. Although pasteurisation of milk might affect the binding characteristics of FBP, as shown by Gregory (1982) , our in vitro studies with the gastrointestinal model demonstrated that there is still residual binding of folic acid to FBP after gastric passage. Thus, an effect of FBP could be expected if the molar ratio of folic acid to FBP was 1:1 instead of the molar ratio of 7.5:1 as tested in the present study. Therefore, in order to investigate the effect of FBP on the bioavailability of folate in humans, folatefortified milk products with or without an equimolar amount of FBP should be tested in a human intervention study.
The genetic polymorphism of MTHFR in our subjects was examined as a substitution of C to T at nucleotide 677 in the gene results in the production of a MTHFR enzyme with less activity. As MTHFR is involved in the formation of 5-CH 3 -H 4 folate, this polymorphism could influence the outcome of the study. The proportion of the population homozygous at the T677 MTHFR allele is around 12% (Frosst et al, 1995; Malinow et al, 1997; Fohr et al, 2002) . A poor folate status in these individuals leads to higher homocysteine concentrations compared to subjects who are not homozygous for this mutation (Jacques et al, 1996) , and they show enhanced response to folic acid supplementation (Malinow et al, 1997) . In our study, only four of the 69 subjects were homozygous for the T677 allele. As this group behaved similarly to the CC and CT subjects, it was not necessary to take this polymorphism into account when analysing our data.
Questions can be raised as to whether an extra dose of 200 mg of folic acid/d can also improve folate status in persons who have higher folate intakes from food than the subjects of our study. The daily folate intake of the subjects in the current study was below the average folate intake in the Netherlands (De Bree et al, 1997) , which might explain the decrease in folate concentrations in serum and RBCs, and the increase in plasma homocysteine concentrations in the unfortified milk groups during the four weeks of study. In this study, even the subjects in the highest quartile of baseline serum folate concentrations showed the same response on fortification as the other subjects (data not shown). This study also strengthens the evidence that low doses of folic acid in the diet can lower plasma homocysteine levels (Brouwer et al, 1999b; Johansson et al, 2002; Van Oort et al, 2003) . Even though our subjects had a mean plasma homocysteine concentration of 8.75 mmol/l at baseline, the low dose of folic acid was able to lower plasma homocysteine concentrations. It is interesting to note that we were unable to detect any unmodified folic acid in the serum of those subjects who received milk supplemented with folic acid (o1% of total concentration; analysis carried out by RB van Breemen, University of Illinois at Chicago, personal communication, data not shown). This does not support the concern of others, who detected unmetabolised folic acid in serum of subjects consuming fortified food and supplements, and which might be an unwanted effect (Kelly et al, 1997; Lucock 2004) .
In summary, milk was found to be a suitable product for folic acid fortification to increase folate status in humans. This study clearly showed that milk fortified with folic acid enhanced concentrations in serum and RBCs, and decreased plasma total homocysteine concentrations within 4 weeks. No significant effect of endogenous FBP in pasteurised milk on the bioavailability of folic acid from fortified milk was found.
